A Type 1 diabetes genetic risk score can discriminate monogenic autoimmunity with diabetes from early onset clustering of polygenic autoimmunity with diabetes
Johnson, MBJ; Patel, K; De Franco, E; et al.Houghton, J; McDonald, T; Ellard, S; Flanagan, S; Hattersley, A
Date: 7 February 2018
Article
Journal
Diabetologia
Publisher
Springer Verlag
Publisher DOI
Abstract
Aims/hypothesis
Identifying individuals suitable for monogenic autoimmunity testing and gene discovery studies is challenging: early-onset type 1 diabetes mellitus (T1D) can cluster with additional autoimmune diseases due to shared polygenic risk and islet and other organ specific autoantibodies are present in both monogenic and ...
Aims/hypothesis
Identifying individuals suitable for monogenic autoimmunity testing and gene discovery studies is challenging: early-onset type 1 diabetes mellitus (T1D) can cluster with additional autoimmune diseases due to shared polygenic risk and islet and other organ specific autoantibodies are present in both monogenic and polygenic aetiologies. We aimed to assess if a type 1 diabetes genetic risk score (T1D-GRS) could identify monogenic autoimmune diabetes and be useful to prioritise individuals for gene discovery studies.
Methods
We studied 79 individuals with diabetes and at least 1 additional autoimmune disease diagnosed before 5 years. We screened all participants for the 7 genes known to cause monogenic autoimmunity that can include diabetes (AIRE, IL2RA, FOXP3, LRBA, STAT1, STAT3, STAT5b). We genotyped the top 10 risk alleles for type 1 diabetes, including HLA and non-HLA loci, to generate a T1D-GRS.
Results
47% (37/79) of individuals had mutations in the monogenic autoimmunity genes. The T1D-GRS was lower in these individuals compared to those without mutations in these genes (median 9th vs. 49th centile of type 1 diabetes controls, p<0.0001). Age of diabetes diagnosis and T1D-GRS combined to be highly discriminatory of monogenic autoimmunity (ROC-AUC: 0.88). Most individuals without a mutation in a known gene had a high T1D-GRS, suggesting they have polygenic clustering of type 1 diabetes and additional autoimmunity and should not be included in gene discovery studies.
Conclusions
We have shown that the T1D-GRS can identify individuals likely to have monogenic autoimmunity helping both diagnostic testing and novel monogenic autoimmunity gene discovery. Individuals with monogenic autoimmunity have a different clinical course to those with polygenic type 1 diabetes and can respond well to therapies targeting the underlying genetic defect.
Institute of Biomedical & Clinical Science
Collections of Former Colleges
Item views 0
Full item downloads 0
Related items
Showing items related by title, author, creator and subject.
-
Recruitment, retention, and training of people with type 2 diabetes as diabetes prevention mentors (DPM) to support a healthcare professional-delivered diabetes prevention program: the Norfolk Diabetes Prevention Study (NDPS)
Garner, NJ; Pascale, M; France, K; et al. (BMJ Publishing Group, 27 May 2019)Objective: Intensive lifestyle interventions reduce the risk of type 2 diabetes in populations at highest risk, but staffing levels are usually unable to meet the challenge of delivering effective prevention strategies to ... -
Study Protocol: The Norfolk Diabetes Prevention Study [NDPS]: a 46 month multi - centre, randomised, controlled parallel group trial of a lifestyle intervention [with or without additional support from lay lifestyle mentors with Type 2 diabetes] to prevent transition to Type 2 diabetes in high risk groups with non - diabetic hyperglycaemia, or impaired fasting glucose.
Pascale, M; Murray, N; Bachmann, M; et al. (BioMed Central, 6 January 2017)BACKGROUND: This 7 year NIHR programme [2011-2018] tests the primary hypothesis that the NDPS diet and physical activity intervention will reduce the risk of transition to type 2 diabetes (T2DM) in groups at high risk of ... -
Challenges and solutions for diabetes early career researchers in the COVID-19 recovery: Perspectives of the Diabetes UK Innovators in Diabetes
Gage, MC; Harrington, D; Brierley, GV; et al. (Wiley / Diabetes UK, 28 September 2021)The COVID-19 pandemic has put diabetes at the forefront of conversation. The prevalence of type 2 diabetes in the United Kingdom is high1 and has links to adverse COVID-19 outcomes.2 Research investigating the links between ...